Trial of Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase (MEK) Inhibitor



Status:Recruiting
Conditions:Cancer, Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:Any
Updated:11/18/2012
Start Date:August 2009

Use our guide to learn which trials are right for you!

Phase II Trial With Safety-Run-In of MEK Inhibitor AS703026 In Subjects With Poor Prognosis Acute Myeloid Leukemia and Other Hematological Malignancies


The research trial is testing the experimental drug AS703026 in the treatment of blood and
bone marrow cancers. The study will be run in two parts:

Phase 1: Will determine the maximum tolerated dose of the study drug in subjects with
advanced hematological malignancies.

Phase II: Will assess the anti-leukemic activity of the study drug in older subjects with
newly diagnosed poor prognosis Acute Myeloid Leukemia who are not candidates for intensive
chemotherapy.


Inclusion criteria:

Phase 1:

1. Subjects with one of the following conditions:

- Primary or secondary Acute Myeloid Leukemia, pathologically confirmed according
to World Health Organization classification

- Subjects with myelodysplastic syndrome, International Prognostic Scoring System
Int-2 or high risk who are resistant or intolerant to standard treatment and not
candidates for transplantation,

- Subjects with relapsed or refractory multiple myeloma, who have failed or are
intolerant to at least two prior therapies including thalidomide, lenalidomide
and bortezomib,

- Subjects with advanced myeloproliferative disorders for whom no established
treatment options are available,

- Subjects with acute lymphocytic leukemia, relapsed, refractory or intolerant to
standard treatment and for whom no effective treatment options are available,

2. Age greater than or equal to 18 years.

3. Subjects have read and understood the Informed Consent Form

4. Subjects and their partners must be willing to avoid pregnancy during the trial

Phase 2:

1. Subjects with newly diagnosed primary or secondary Acute Myeloid Leukemia
pathologically confirmed according to World Health Organization classification who
have NOT been exposed to any prior therapy for Acute Myeloid Leukemia.

2. Subjects meet at least one of the following conditions:

- Age greater than or equal to 75 years OR

- Age greater than or equal to 60 and less than 75 years with at least one of the
following poor prognostic factors:

- Secondary Acute Myeloid Leukemia

- At least one of the following unfavorable cytogenetic abnormalities:
del(5q), -5, -7, del(7q), abn 3q, 9q, 11q, 20q, 21q, 17p, t(6;9), t(9;22)
or complex karyotypes (greater than or equal to 3 unrelated abnormalities)

- Eastern Cooperative Oncology Group status 2

3. Subjects have read and understood the Informed Consent Form

4. Subjects and their partners must be willing to avoid pregnancy during the trial and
until 1 month after the last trial drug administration.

Exclusion Criteria:

Phase 1 and Phase 2:

1. Eastern Cooperative Oncology Group performance status 3 or greater,

2. Hyperleukocytosis with greater than 30x10 to the ninth power per L leukemia blasts in
peripheral blood,

3. Acute promyelocytic leukemia

4. Administration of any antineoplastic therapy within at least 2 weeks

5. Participation in other clinical trials within at least 2 weeks of the first AS703026
dose,

6. Active central nervous system leukemia,

7. Active and uncontrolled infection

8. Other significant disease

9. Major surgery within two weeks prior to trial entry,

10. Liver function tests above specific limits

11. International normalized ratio greater than 1.5 x ULN unless on treatment with
warfarin,

12. For female subjects: pregnant or breast-feeding,

13. Subjects with solid tumors, for whom the Investigator has clinical suspicion of
active disease at the time of enrolment.

14. Legal incapacity or limited legal capacity.
We found this trial at
3
sites
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Baltimore, Maryland 21231
410-955-6190
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials